MY010: Anti-Allergen Antibodies for the Treatment of Fagales Pollen Allergy

Prevalence of birch pollen allergy is up to 30% in industrialized countries. Birch is a member of the order Fagales, which includes other potent elicitors of spring pollinosis, such as alder, hazel and oak. The high IgE cross-reactivity within Fagales due to PR-10-like proteins is well known. Therefore, to develop a successful anti-allergen antibody therapy for birch pollen and related allergies it becomes important to target as many PR-10 proteins as possible. Mabylon has developed a human antibody discovery platform that allowed us to clone and express Bet v 1-specific recombinant human antibodies from allergic patients. Upon screening our human-derived anti-birch antibody library, we selected the most potent antibody cocktail, MY010, as anti-allergen antibody immunotherapy for the treatment of birch-related pollen allergies. The selected antibodies are binding Bet v 1 with high affinity and targeting disease-relevant proteins and epitopes. MY010 shows broad cross-reactivity within the PR-10 protein family. It prevents patients’ IgE binding to the allergens and effector cell degranulation upon stimulation with multiple Fagales extracts such as oak, hazel and alder in addition to birch. MY010 is efficacious in patient samples originating from different geographical regions. In conclusion, MY010 holds great promise as a novel therapy for birch and related pollen allergies, with a predicted immediate onset of protection and good safety profile. It shows significant cross-reactivity to the different PR-10 pollen allergens and efficacy in patient samples from different geographical regions and to multiple birch-related extracts.